Advertisement
Advertisement
January 15, 2024
Mentice’s Ankyras Decision Support Software Cleared for Intracranial Aneurysm Procedure Planning
January 15, 2024—Mentice recently announced FDA 510(k) clearance for its Ankyras clinical decision support application. The software is designed to assist interventional neuroradiologists in selecting the most suitable flow diverter before interventional treatment of intracranial aneurysms. In the European Union, Ankyras has received CE Mark approval.
According to the company, Ankyras is intended to provide an intuitive and precise solution for clinical treatment planning, leading to more accurate prediction than traditional methods. The application features various functionalities to investigate device and treatment options in greater detail. Unique morphological assessment metrics that provide users with a comprehensive and interactive analysis of all artery segments. The platform’s technology enables users to evaluate final device length, local expansion, and porosity, and precisely align the centerline to create accurate simulations for specific devices.
The company advised it plans to continue improving the Ankyras solution by incorporating advanced functionalities and more treatment modalities, as well as integrating it with other Mentice solutions, especially the recently acquired Biomodex line of biorealistic haptic simulators.
Advertisement
Advertisement
